Dr. Saiama N. Waqar
Claim this profileWashington University School of Medicine
Expert in Lung Cancer
Expert in Non-Small Cell Lung Cancer
24 reported clinical trials
48 drugs studied
About Saiama N. Waqar
Education:
- Obtained MBBS from Aga Khan University Hospital, Karachi, Pakistan (1996-2001).
- Earned MSCI from Washington University School of Medicine, St. Louis, MO.
Experience:
- Currently serves as Professor of Medicine and Director of Education for Oncology at Washington University School of Medicine, St. Louis, MO.
- Held the position of Associate Professor of Medicine and Research Director for Thoracic Oncology at the same institution.
- Actively involved in interviewing for residency and fellowship programs at Washington University since 2013.
- Engaged in various committees and grants at Washington University and Siteman Cancer Center since 2011.
Area of expertise
1Lung Cancer
Global LeaderStage IV
Stage III
RET positive
2Non-Small Cell Lung Cancer
Global LeaderStage IV
Stage III
RET positive
Affiliated Hospitals
Clinical Trials Saiama N. Waqar is currently running
Neoantigen Vaccine + Durvalumab
for Small Cell Lung Cancer
This trial is testing a custom-made vaccine combined with an immune-boosting drug called durvalumab. It aims to help patients with advanced small cell lung cancer, a severe type of lung cancer that has spread widely. The vaccine targets unique markers on cancer cells, while durvalumab helps the immune system fight these cells more effectively.
Recruiting1 award Phase 212 criteria
APL-101 + Osimertinib
for Non-Small Cell Lung Cancer
In this study, patients with metastatic non-small cell lung cancer that is EGFR-mutated, who have received at least 8 and not more than 12 weeks of treatment with osimertinib without demonstrating disease progression, will receive APL-101 in combination with osimertinib until progression. Dosing of APL-101 will be escalated until the maximum tolerated dose is determined, at which point 10 additional patients will be enrolled at that dose in the expansion cohort.
Recruiting1 award Phase 1 & 28 criteria
More about Saiama N. Waqar
Clinical Trial Related3 years of experience running clinical trials · Led 24 trials as a Principal Investigator · 10 Active Clinical TrialsTreatments Saiama N. Waqar has experience with
- Durvalumab
- Atezolizumab
- Ramucirumab
- Pembrolizumab
- Docetaxel
- AL8326
Breakdown of trials Saiama N. Waqar has run
Lung Cancer
Non-Small Cell Lung Cancer
Small Cell Lung Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Saiama N. Waqar specialize in?
Saiama N. Waqar focuses on Lung Cancer and Non-Small Cell Lung Cancer. In particular, much of their work with Lung Cancer has involved Stage IV patients, or patients who are Stage III.
Is Saiama N. Waqar currently recruiting for clinical trials?
Yes, Saiama N. Waqar is currently recruiting for 9 clinical trials in Saint Louis Missouri. If you're interested in participating, you should apply.
Are there any treatments that Saiama N. Waqar has studied deeply?
Yes, Saiama N. Waqar has studied treatments such as Durvalumab, Atezolizumab, Ramucirumab.
What is the best way to schedule an appointment with Saiama N. Waqar?
Apply for one of the trials that Saiama N. Waqar is conducting.
What is the office address of Saiama N. Waqar?
The office of Saiama N. Waqar is located at: Washington University School of Medicine, Saint Louis, Missouri 63110 United States. This is the address for their practice at the Washington University School of Medicine.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.